Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Glaucoma in perspective

- PMLiVE

Blue Latitude’s industry-first praised at PMEA

Support for Lilly and its Medical Information Cascade wins Innovation Award

- PMLiVE

Alexion’s rare bone disorder therapy rejected by NICE

Draft guidance rules Strensiq does not have a compelling enough evidence base

- PMLiVE

GSK’s severe asthma therapy Nucala gets EU nod

Becomes the first IL-5 inhibitor to be approved in the EU

- PMLiVE

Purdue Pharma appoints Dr Alan Dunton

He joins the pain specialist as senior VP of research and development

Lucid team : because you’re worth it!

Lucid group reward the team for an amazing year

Lucid Group Communications Limited

- PMLiVE

Novo Nordisk says Victoza outperforms SGLT2 inhibitors

Comparesthe GLP-1 agonist to Invokana, Jardiance and Farxiga

EISAI

Eisai expands in China with generics company acquisition

BuysLiaoning TianYi Biological Pharmaceutical

Second patient death in Zafgen’s obesity drug trial

Furtherblood clot incident seen after FDA hit study with a clinical hold

- PMLiVE

Why is behaviour change so difficult? By Patrick Ladbury, Communications Manager at the National Social Marketing Centre.

Patrick Ladbury nudges us to overcome the barriers to behaviour change. Read on to find out.

Say Communications

Ablynx appoints Robert Zeldin chief medical officer

He previously servedat Merck & Co, Novartis and the FDA

- PMLiVE

Express Scripts to offer alternative to Turing’s Daraprim

Andpromises to share compounded formulation with other healthcare payers

- PMLiVE

Pfizer’s Xalkori approved for wider use in Europe

Labelupdate gives the lung cancer therapy a new first-line indication

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links